Skip to Content

Search

CrossFit Health is an investigation into the ills of modern medicine and the wilful abuse of the public’s trust in science. The lessons learned from the legal dismantling of fake science, a crooked journal, and perjuring scientists have given us a forensic view as to how everything might have gone so wrong. We’re calling the combination of runaway medical costs and disease rates–which many profit from but none combat effectively—“The Mess.”

Scientists continue to discover evidence of the therapeutic value of nutritional ketosis for a range of conditions, including Type 2 diabetes, Alzheimer’s, and cancer. Dr. Dominic D’Agostino, an Associate Professor of Molecular Pharmacology and Physiology at the University of South Florida, is at the forefront of research related to the use of ketosis for cancer treatment. During a presentation on July 31, 2019, at the annual CrossFit Health Conference in Madison, Wisconsin, D’Agostino shared his knowledge of the health benefits associated with ketones and presented his latest research on ketosis as an adjuvant treatment for high-grade glioma.

Watch Dr. Dominic D’Agostino: Emerging Applications of Nutritional Ketosis

“I think there is a vast myth that scientists are somehow objective and honest,” Dr. Terence Kealey said during a presentation at a CrossFit Health event at CrossFit Headquarters on March 9, 2019. During his presentation, Kealey discussed the myth of scientific objectivity, drawing examples widely from history as well as his personal experiences within many of the most reputable scientific institutions. “We commit to paradigms, and then we bend the data to it,” Kealey explained. “Now, you get money not for being right; you get money for satisfying the prejudices of the people who sit on the committees in the NIH and NSF.”

Watch Dr. Terence Kealey and the Myth of Scientific Objectivity

Dr. Maryanne Demasi lists several examples that indicate people have steadily been losing confidence in the medical sciences and professions since the 1980s. She also presents a few factors she believes have contributed to the trend. For instance, President Ronald Reagan’s defunding of the NIH and private industry's subsequent infiltration of the medical sciences have led to a litany of corrupt practices that have exacerbated the problem and put lives at risk, she explains.

Read MoreIn science we trust — or do we?

Dr. Jason Fung, MD, is a nephrologist and expert in the use of intermittent fasting and low-carbohydrate diets for the treatment of Type 2 diabetes. In this presentation, delivered on Aug. 2, 2018, at the 2018 CrossFit Health Conference in Madison, Wisconsin, Fung shares his first-hand experiences with “The Mess” in the medical sciences and discusses how he shifted his research and clinical practices as a result of those experiences. He explains why long-term weight loss is so difficult, introduces the concept of therapeutic fasting, and dispels common myths associated with the fasting process.

WatchDr. Jason Fung: Fasting as a Therapeutic Option for Weight Loss

In 2013, Dr. Maryanne Demasi was investigating the clinical trial data on statins when she learned the raw data had been kept secret, held by a group of researchers called the Cholesterol Treatment Trialists (CTT) out of Oxford University. Here, Demasi explains why such secrecy undermines what she terms "the bedrock of science: contestability and replicability." She also notes the ways the landscape has changed since 2013, opening the door for independent review of the data on statins and other drugs.

Read MoreThe secret life of data

On June 29, 2019, The New York Times published a report entitled “FDA Names 16 Brands of Dog Food That May Be Linked to Canine Heart Disease.” The story was an update to previous coverage of an FDA investigation into the nutritional causes of a rare canine heart disease called dilated cardiomyopathy (DCM). The investigation, ongoing since July of last year, is a unique example of a veterinary nutrition story managing to transcend the veterinary community and grab the attention of the pet-owning public. Unfortunately, the majority of the reports on this story ignore the financial conflicts of interest possessed by the veterinarians at the heart of the FDA’s investigation, and all mischaracterize the actual state of the scientific record concerning canine DCM.

Read MoreBad Science and Financial Conflicts of Interest Plague the FDA’s Investigation Into “Grain-Free” Pet Foods and Dilated Cardiomyopathy
Library of economics and liberty

"Marcia Angell of Harvard Medical School and the author of 'The Truth About the Drug Companies' talks with EconTalk host Russ Roberts about the impact of pharmaceutical companies on academic research, clinical trials and the political process. Angell argues that the large pharmaceutical companies produce little or no innovation and use their political power to exploit consumers and taxpayers."

Listen Angell on Big Pharma

The 2019 CrossFit Health Conference will take place July 31 at the Monona Terrace in Madison, Wisconsin. There, CrossFit Health will continue its annual tradition of bringing together world-class thinkers from the scientific and CrossFit communities to explore the devolution of science and the ills of modern medicine. This year, speakers will discuss three central themes — the war on cholesterol and fat, the metabolic effects of low-carb diets, and the widespread sacrifice of scientific truth on the altar of the pharmaceutical industry — all through the lens of their personal experiences with “The Mess.”

Read MoreThe 2019 CrossFit Health Conference

In 1993, Prof. Peter C. Gøtzsche co-founded the famous Cochrane Collaboration, an organization formed to conduct systematic reviews of medical research in the interest of promoting unbiased evidence-based science. During his tenure with Cochrane, Gøtzsche fought to uphold its original values. However, when Gøtzsche attempted to correct the path of consensus science or point to industry-related bias, Cochrane sought to censor him and eventually expelled him in 2018 after what he calls a Kafkaesque “show trial.” Here, Gøtzsche shares the research that led to his fallout with Cochrane as well as his firsthand experiences witnessing the organization’s moral collapse.

Watch Peter C. Gøtzsche: Death of a Whistleblower and Cochrane’s Moral Collapse

In this October 2018 editorial, Michael Hengartner and Martin Plöderl argue trials investigating the impact of antidepressants show statistically significant but not clinically significant effects, and even these meager effects may be eroded by known biases.

Read MoreStatistically Significant Antidepressant-Placebo Differences on Subjective Symptom-Rating Scales Do Not Prove that the Drugs Work: Effect Size and Method Bias Matter!

Comments on undefined